The Pharma Data

AUGUST 30, 2021

Results were presented at the ESC Congress 2021, organized by the European Society of Cardiology (ESC). In three clinical trials, patients taking Leqvio maintained LDL-C reduction throughout each six-month dosing interval 8,10. In the first analysis, patients with established CeVD treated with Leqvio achieved an average 55.2%

RNA 52

RNA Trials Production Containment 52

The Pharma Data

AUGUST 29, 2020

Presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology, the analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran) from the Phase III trials.

Medicine 52

Medicine Containment Trials Production 52

The Pharma Data

NOVEMBER 4, 2020

Expanded m edical society recommendations in support of the efficacy and safety of VASCEPA : The European Society of Cardiology expanded their guidelines to recommend use of VASCEPA in treating acute coronary syndrome patients. In addition, Amarin recognized licensing and royalty revenue of approximately $1.3 commercial team. “In

Sales 40

Sales Production Cardiology Marketing 40

The Pharma Data

OCTOBER 29, 2020

We remain focused on continuing to serve patients, protecting the health and safety of our employees and the communities in which we live and work, and supporting patients in clinical trials. The COVID-19 impact has varied by study and program, but there has been little timing impact on fully-enrolled trials.

Sales 40

Sales Clinical Trials Clinical Trials Production 40

XTalks

AUGUST 2, 2023

It contains the antiviral medications nirmatrelvir and ritonavir. Late in 2022, AbbVie partnered with HotSpot Therapeutics and announced an exclusive worldwide collaboration and option to license agreement for their interferon regulatory factor 5 (IRF5) inhibitor program for autoimmune disease treatment. billion in 2022. billion ($3.65

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

SEPTEMBER 15, 2020

The company announced the initiation of its Phase 1b clinical trial to evaluate the safety of a novel investigational therapeutic for COVID-19, PF-07304814. Disclosure Notice: The information contained in this release is as of September 15, 2020. Protease Inhibitor Program. and -50.4%

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

APRIL 26, 2021

billion declined, mainly due to the USD 650 million upfront payment to in-license tislelizumab from BeiGene. This decline was mainly due to the USD 650 million upfront payment to in-license tislelizumab from BeiGene and lower operating income adjusted for non-cash items, partly offset by favorable changes in working capital.

Sales 40

Sales Medicine Production Manufacturing 40